# US 2014/0193849 A1 · Glucose-peg conjugates for reducing glucose transport into a cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193849 A1
- Document ID: US20140193849A1
- Status: Published application
- Kind: A1
- Application number: 14/149,493
- Filed: 2014-01-07
- Published: 2014-07-10
- Earliest claimed: 2008-12-11
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology and Research
- Inventors: Karthikeyan Narayanan; Andrew Chwee Aun Wan; Jackie Y. Ying; Nandanan Erathodiyil
- Web page: https://patentgrep.com/patent/US20140193849A1

## CPC

- C08G 65/00: Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/69: Boron compounds
- A61P 35/00: Antineoplastic agents
- C07C 235/08: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07H 15/08: Polyoxyalkylene derivatives
- G01N 33/5091: {for testing the pathological state of an organism}
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A glucose-PEG conjugate comprising
wherein each n is independently from 2 to 500.

### Claim 25 (depends on 24)

The glucose-PEG conjugate of claim 24 further comprising a detectable label.

### Claim 26 (depends on 25)

The glucose-PEG conjugate of claim 25 wherein the detectable label is a PET label, an SPECT label, an MRI label, a quantum dot label, a coloured label, a fluorescent label, a radiolabel or a label that may be detected by an antibody or antibody fragment.

### Claim 27 (depends on 25)

The glucose-PEG conjugate of claim 25 comprising

### Claim 28 (depends on 25)

A method of imaging a hyper-proliferative cell comprising contacting a hyper-proliferative cell with a glucose-PEG conjugate of claim 25; and detecting the detectable label.

### Claim 29 (depends on 28)

The method of claim 28 wherein detecting involves fluorescence microscopy, positron emission tomography imaging, single photon emission computed tomography imaging or magnetic resonance imaging.

### Claim 30 (depends on 28)

The method of claim 28 wherein the cell is associated with a proliferative disorder.

### Claim 31 (depends on 30)

The method of claim 30 wherein contacting comprises administering an effective amount of the glucose-PEG conjugate at the site of a hyper-proliferating cell in a subject.

### Claim 32 (depends on 28)

The method of claim 28 further comprising contacting the cell with a chemotherapeutic agent.

### Claim 33 (depends on 30)

The method of claim 30 further comprising contacting the cell with a chemotherapeutic agent.

### Claim 34 (depends on 24)

A pharmaceutical composition comprising a glucose-PEG conjugate of claim 24.